Determinants of branded prescription medicine prices in OECD countries.

摘要: This paper investigates the determinants of prices branded prescription medicines across different regulatory settings and health care systems, taking into account their launch date, patent status, market dynamics context in which they diffuse. By using volume-weighted price indices, this analyzes levels for a basket differences 15 OECD countries, including United States key European impact distribution margins generic entry on public to what extent innovation, by means introducing newer classes medicines, contributes formation countries. In doing so, seeks understand factors that contribute existing whether at an ex-factory or retail level. The evidence shows are higher than those other but not as high widely thought. Large mainly observed level, these consumers payers pay. Cross-country actually expected and, when controlling exchange rates, can be even smaller. Product age has significant effect all after having controlled factors. Price convergence is countries compared with older medicines. There no originator brand fall States, phenomenon known ‘generics paradox’. Finally, taxes important several study To remuneration chain taxation directly proportionately linked product likely persist over time.